EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Rifaximin‐α in Patients With Recurrent Episodes of Hepatic Encephalopathy Due to Cirrhosis Reduces Healthcare Utilization

Diederick J van Doorn iD, Kirsi M A van Eekhout, Koos de Wit iD, L C Baak, Michael Klemt-Kropp iD, Bart J Verwer, Philip Friederich, Gijs J de Bruin, Xander G Vos, Joost P H Drenth iD, R Bart Takkenberg iD

United European Gastroenterology Journal · 2025-07 · 13 (6) · 938-945

DOI: 10.1002/ueg2.12767 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift United European Gastroenterology Journal, online erschienen am 30.04.2025. Verfasst von Diederick J van Doorn und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam UMC, University of Amsterdam, Amsterdam…. Hauptthemen laut MEDLINE: Hepatic Encephalopathy, Rifaximin, Liver Cirrhosis, Secondary Prevention. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Norgine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Hepatic encephalopathy is a frequent complication of cirrhosis. Rifaximin‐α has been included in guidelines for secondary prevention of hepatic encephalopathy, but there are few real‐world data on its efficacy and impact on healthcare utilization. In this study, we aimed to assess the effect of rifaximin‐α on healthcare utilization.

Method

We conducted a cohort analysis in patients from seven hospitals in the Netherlands, who received rifaximin‐α as secondary prophylaxis for hepatic encephalopathy. Data were compared 6 months before and 6 months after the prescription of rifaximin‐α. The primary endpoint was the effect of rifaximin‐α on healthcare utilization. Secondary endpoint was the effect of rifaximin‐α on healthcare costs.

Results

We included 126 patients (65% male; median age 68) with a median Model for End‐stage Liver Disease score of 15. The mean number of hepatic encephalopathy episodes after starting rifaximin‐α was lower than before starting rifaximin‐α (0.9 vs. 2.2; p < 0.001). Mean healthcare utilization decreased from 6.1 contacts in the 6 months before rifaximin‐α to 3.3 contacts in the 6 months after starting rifaximin‐α ( p < 0.001). The mean number of hospital admissions decreased from 1.7 admissions per patient to 1.0 admissions after starting rifaximin‐α ( p < 0.001). The mean number of outpatient visits also decreased after starting rifaximin‐α (2.4 visits per patient to 1.7; p = 0.001). Annual costs per patient before starting rifaximin‐α were €13,320. This was similar to the costs after rifaximin‐α was prescribed (€13,120).

Conclusion

Rifaximin‐α significantly reduced the number of episodes of hepatic encephalopathy, the number of hospital admissions as well as the number of outpatient and emergency department visits, contributing to a reduction in healthcare utilization. There was no reduction in overall costs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatic EncephalopathyRifaximinLiver CirrhosisSecondary PreventionRifamycinsPatient Acceptance of Health CareGastrointestinal AgentsHumansMaleFemaleAgedNetherlandsMiddle AgedRecurrenceHealth Care CostsTreatment OutcomeHospitalization

Stichwörter der Autor:innen

MELDcostshospital admissionsmicrobiomemicrobiotanon‐adsorbable antibioticsportal hypertensionpreventionprophylaxisrifaximin

Substanzen

RifaximinRifamycinsGastrointestinal Agents

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
  • Department of Gastroenterology and Hepatology, OLVG, Amsterdam, the Netherlands.
  • Department of Gastroenterology and Hepatology, Noordwest Ziekenhuisgroep, Alkmaar, the Netherlands.
  • Department of Gastroenterology and Hepatology, Spaarne Gasthuis, Hoofddorp, the Netherlands.
  • Department of Gastroenterology and Hepatology, Meander Medisch Centrum, Amersfoort, the Netherlands.
  • Department of Gastroenterology and Hepatology, Tergooi MC, Hilversum, the Netherlands.

ORCID-Profile: Diederick J van Doorn, Koos de Wit, Michael Klemt-Kropp, Joost P H Drenth, R Bart Takkenberg

Förderung

  • Norgine

Zitieren

APA

van Doorn, D. J., van Eekhout, K. M. A., de Wit, K., Baak, L. C., Klemt-Kropp, M., Verwer, B. J., Friederich, P., de Bruin, G. J., Vos, X. G., Drenth, J. P. H., & Takkenberg, R. B. (2025). Rifaximin‐α in Patients With Recurrent Episodes of Hepatic Encephalopathy Due to Cirrhosis Reduces Healthcare Utilization. United European Gastroenterology Journal, 13(6), 938-945. https://doi.org/10.1002/ueg2.12767

Vancouver

van Doorn DJ, van Eekhout KMA, de Wit K, Baak LC, Klemt-Kropp M, Verwer BJ, et al. Rifaximin‐α in Patients With Recurrent Episodes of Hepatic Encephalopathy Due to Cirrhosis Reduces Healthcare Utilization. United European Gastroenterology Journal. 2025;13(6):938-945. doi:10.1002/ueg2.12767

BibTeX
@article{vanDoorn2025,
  author = {van Doorn, Diederick J and van Eekhout, Kirsi M A and de Wit, Koos and Baak, L C and Klemt-Kropp, Michael and Verwer, Bart J and Friederich, Philip and de Bruin, Gijs J and Vos, Xander G and Drenth, Joost P H and Takkenberg, R Bart},
  title = {Rifaximin‐α in Patients With Recurrent Episodes of Hepatic Encephalopathy Due to Cirrhosis Reduces Healthcare Utilization},
  journal = {United European Gastroenterology Journal},
  year = {2025},
  volume = {13},
  number = {6},
  pages = {938--945},
  doi = {10.1002/ueg2.12767}
}
Kostenlos starten →